

**PRESS
RELEASE****A BRAND NAME FOR THE SECOND SUBLINGUAL
DESENSITIZATION TABLET PRODUCED BY STALLERGENES**

Antony, France (August 27, 2009) - Stallergenes has announced that the sublingual desensitization tablet for allergic rhinitis caused by exposure to dust mites has been given the following brand name:

“ACTAIR®”

The brand name ACTAIR® alludes to both the allergen in question (“Ac” for “acarid”, which is the scientific term for mites, derived from the Latin “acari”), and the respiratory system (“air” for “airways”). It also indicates that this pharmaceutical product is part of Stallergenes’ STALAIR® development program.

The STALAIR® development program has been designed to develop EBM-documented, registered sublingual desensitization tablets, based on allergens that cater for the unmet medical needs of patients suffering from moderate to severe allergic rhinitis and rhinoconjunctivitis, not controlled by their usual medical treatment. This program consists in the development of 5 tablets for the main allergens triggering more than 80% of allergies: grass pollens, house dust mites, birch pollen, ragweed pollen and Japanese cedar pollen.

To date, the STALAIR® program includes 13 phase I to III clinical trials, 7 of which have already been completed and 6 of which are currently underway. Its clinical development is proceeding according to schedule. These trials have included a total of 5000 patients.

The first product resulting from this program – the ORALAIR® sublingual tablet for grass pollen desensitization – has been marketed in Germany in adult indications since September 2008 and in pediatric indications since January 2009. A mutual recognition procedure enabling to register this product in most European countries is undergoing.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, such as rhinoconjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 21% of its turnover, in gross terms, to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.

In 2008, Stallergenes had a turnover of 171 million euros and more than 500,000 patients were treated with Stallergenes desensitization products.

Stallergenes is listed on Euronext Paris (Compartment B) and is part of the sample composing the SBF 120 index.

ISIN code: FR0000065674
Reuters code: GEN.PA
Bloomberg code: GEN.FP

GENP
LISTED
NYSE
EURONEXT

Additional information is available at <http://www.stallergenes.com>



Contacts

Press Relations

Lise Lemonnier – Communication Manager
Tél. : + 33 1 55 59 20 96
e-mail : llemonnier@stallergenes.fr

Investor Relations

Lucile de Fraguier – Pavie Finance
Tél. : + 33 1 42 15 04 39
e-mail : contact@pavie-finance.com